The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
Open accessAbstract
BACKGROUND: Over 150,000 Malawians have started antiretroviral therapy (ART), in which first-line therapy is stavudine/lamivudine/nevirapine. We evaluated drug resistance patterns among patients failing first-line ART on the basis of clinical or immunological criteria in Lilongwe and Blantyre, Malawi. METHODS: Patients meeting the definition of ART failure (new or progressive stage 4 condition, CD4 cell count decline more than 30%, CD4 cell count less than that before treatment) from January 2006 to July 2007 were evaluated. Among those with HIV RNA of more than 1000 copies/ml, genotyping was performed. For complex genotype patterns, phenotyping was performed. RESULTS: Ninety-six confirmed ART failure patients were identified. Median (interquartile range) CD4 cell count, log10 HIV-1 RNA, and duration on ART were 68 cells/microl (23-174), 4.72 copies/ml (4.26-5.16), and 36.5 months (26.6-49.8), respectively. Ninety-three percent of samples had nonnucleoside reverse transcriptase inhibitor mutations, and 81% had the M184V mutation. The most frequent pattern included M184V and nonnucleoside reverse transcriptase inhibitor mutations along with at least one thymidine analog mutation (56%). Twenty-three percent of patients acquired the K70E or K65R mutations associated with tenofovir resistance; 17% of the patients had pan-nucleoside resistance that corresponded to K65R or K70E and additional resistance mutations, most commonly the 151 complex. Emergence of the K65R and K70E mutations was associated with CD4 cell count of less than 100 cells/microl (odds ratio 6.1) and inversely with the use of zidovudine (odds ratio 0.18). Phenotypic susceptibility data indicated that the nucleoside reverse transcriptase inhibitor backbone with the highest activity for subsequent therapy was zidovudine/lamivudine/tenofovir, followed by lamivudine/tenofovir, and then abacavir/didanosine. CONCLUSION: When clinical and CD4 cell count criteria are used to monitor first-line ART failure, extensive nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor resistance emerges, with most patients having resistance profiles that markedly compromise the activity of second-line ART.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Self-citationGulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Ferradini, L., Jeannin, A., Pinoges, L., Izopet, J., Odhiambo, D., Mankhambo, L., Karungi, G., Szumilin, E., Balandine, S., Fedida, G., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68580-2 · Cited by 450
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268
Marconi, V. C., Sunpath, H., Lu, Z., Gordon, M., Koranteng‐Apeagyei, K., Hampton, J., Carpenter, S., Giddy, J., Ross, D., Holst, H., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587109 · Cited by 239
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Brenner, B. G., Oliveira, M., Doualla-Bell, F., Moisi, D. D., Ntemgwa, M., Frankel, F., Essex, M., & Wainberg, M. A. (2006) · AIDS · doi:10.1097/01.aids.0000232228.88511.0b · Cited by 226
Arribas, J. R., Pulido, F., Delgado, R. B., Lorenzo, A., Miralles, P., Arranz, A., González‐García, J., Cepeda, C., Hervás, R., Paño, J. R., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000180077.59159.f4 · Cited by 151
Parikh, U. M., Bacheler, L. T., Koontz, D. L., & Mellors, J. W. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4971-4977.2006 · Cited by 130
Scaling up antiretroviral treatment in resource-poor settings
Harries, A. D., Schouten, E. J., & Libamba, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68809-0 · Cited by 130
Cited by
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission
Chasela, C. S., Hudgens, M. G., Jamieson, D. J., Kayira, D., Hosseinipour, M. C., Kourtis, A. P., Martinson, F., Tegha, G., Knight, R. J., Ahmed, Y. I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911486 · Cited by 440
Self-citationGupta, R. K., Jordan, M. R., Sultan, B. J., Hill, A., Davis, D. H., Gregson, J., Sawyer, A. W., Hamers, R. L., Ndembi, N., Pillay, D., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61038-1 · Cited by 364
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Boulle, A., Van Cutsem, G., Hilderbrand, K., Cragg, C., Abrahams, M., Mathee, S., Ford, N., Knight, L., Osler, M., Myers, J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328333bfb7 · Cited by 264
Metadata
- Authors
- Hosseinipour, M. C., van Oosterhout, J. J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., Fiscus, S. A., Nelson, J. A., Eron, J. J., & Kumwenda, J.
- Venue
- AIDS
- Published
- 2009-06-01
- Volume
- 23
- Issue
- 9
- Pages
- 1127-1134
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2029246165
- Cited by
- 288
- References
- 18
- FWCI
- 33.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. https://app.cochat.ai/papers/10.1097/qad.0b013e32832ac34e
- The paper
- Hosseinipour, M. C., van Oosterhout, J. J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., Fiscus, S. A., Nelson, J. A., Eron, J. J., & Kumwenda, J. (2009). The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. https://doi.org/10.1097/qad.0b013e32832ac34e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.